Please login to the form below

Not currently logged in
Email:
Password:

siponimod

This page shows the latest siponimod news and features for those working in and with pharma, biotech and healthcare.

Novartis gains EU approval for relapsing MS drug Kesimpta

Novartis gains EU approval for relapsing MS drug Kesimpta

The new EU approval for Kesimpta builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).

Latest news

  • J&J’s MS drug ponesimod receives approval in the US J&J’s MS drug ponesimod receives approval in the US

    Now that Ponvory has received regulatory approval, it will enter an increasingly crowded market, with rivals including Novartis’ SLP receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod).

  • Novartis’ MS therapy Mayzent approved by NICE Novartis’ MS therapy Mayzent approved by NICE

    Mayzent (siponimod), a sphinogosine 1-phosphate receptor modulator, is the first oral disease-modifying treatment recommended by both NICE and the Scottish Medicines Consortium (SMC) for SPMS with active disease.

  • Novartis wins FDA approval for relapsing MS drug Kesimpta Novartis wins FDA approval for relapsing MS drug Kesimpta

    Kesimpta’s approval in relapsing MS builds on Novartis’ existing presence in the therapy area, which includes its active secondary progressive multiple sclerosis (SPMS) therapy Mayzent (siponimod).

  • Novartis builds its case for novel MS treatment ofatumumab Novartis builds its case for novel MS treatment ofatumumab

    The drug is an important product in Novartis’ growing MS franchise, which currently includes Mayzent (siponimod), a next-generation treatment approved for use in active secondary progressive multiple sclerosis (SPMS).

  • J&J aims for US approval of MS drug ponesimod J&J aims for US approval of MS drug ponesimod

    If approved, ponesimod will compete directly with Novartis’ S1P receptor modulator franchise, which includes Gilenya (fingolimod) and follow-up Mayzent (siponimod), which is approved for secondary progressive forms of MS only

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow

  • Tackling a formidable foe Tackling a formidable foe

    Novartis has announced positive phase III trial data for siponimod, a drug for secondary progressive MS, which reduced the risk of a patient’s disability worsening by 21% after three months

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
Guide
How to embrace behavioural science principles in healthcare MR...